PharmaTher Holdings Ltd. announced that the US FDA has accepted an investigator-initiated IND application to proceed with a Phase II clinical trial evaluating ketamine in the treatment of Amyotrophic Lateral Sclerosis (ALS).
[PharmaTher Holdings Ltd.]
6445212
nan
items
1
apa
0
default
asc
1
170607
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/